Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulised RESP301 in pulmonary tuberculosis
NCT06041919Phase 2Terminated
- Sponsor
- Thirty Respiratory Limited
- Start
- Sep 2023
- Primary completion
- Jul 2024
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RESP301 in pulmonary tuberculosis (TB), sponsored by Thirty Respiratory Limited. Started Sep 2023; status: terminated.
02
Drugs
RESP301
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT06041919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041919.